Bryan Garnier - BioMerieux SA (EYWN) BIOMÃ‰RIEUX: Phantom share plan likely to weight on cEBIT in H1 (results out tomorrow) | NEUTRAL | EUR70

Report

Bryan Garnier

Hugo Solvet

BIOMÃ‰RIEUX: Phantom share plan likely to weight on cEBIT in H1 (results out tomorrow) | NEUTRAL | EUR70

BIOMÃ‰RIEUX - NEUTRAL | EUR70
Phantom share plan likely to weight on cEBIT in H1 (results out tomorrow)

Sequential acceleration of the topline
Phantom share plan likely to weight on profitability
Downside risk reinforced by high valuation levels
H1 Results to be reported tomorrow morning

03/09/2019 3 EN

Underlying

BioMerieux SA

See profile

FR0010096479 France

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Hugo Solvet

Other Reports on these Companies

Independent Investment Research

Monthly LMI Update Independent Investment Research

Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked. This compares to the total dividends of 5 cents per share in FY20. The Board has confirmed that, in...

August 6, 2021 August 6, 2021 10 EN

BusinessWire

bioMÃ©rieux : Informations mensuelles relatives au nombre total de droits de vote et dâ€™actions prÃ©vues par lâ€™article L. 233-8 II du code de commerce et lâ€™article 223-16 du rÃ¨glement gÃ©nÃ©ral de lâ€™AutoritÃ© des marchÃ©s financiers

MARCY Lâ€™ETOILE, France--(BUSINESS WIRE)-- Regulatory News: bioMérieux (Paris:BIM) : Code : BIM - Code ISIN : FR0013280286 Date d’arrêt des informations Nombre d’actions Nombre total de droits de vote 30/11/2019 118 361 220 Nombre de droits de vote théoriques : 197 366 112 N.B. : comme le prévoit le deuxième alinéa de l’article 223-11 du règlement général, le nombre total de droits de vote est calculé sur la base de l’ensemble des actions auxquelles sont attachés des droits de vote, y compris les actions privées de droit de vote bioMérieux socié...

December 6, 2019 December 6, 2019 1 FR

BusinessWire

bioMÃ©rieux : Information RÃ©glementÃ©e â€“ dÃ©claration de transactions sur actions propres

MARCY Lâ€™Ã‰TOILE, France--(BUSINESS WIRE)-- Regulatory News: bioMérieux (Paris:BIM) : En application du règlement européen n°596/2014 du 16 avril 2014 sur les abus de marché (« Règlement MAR ») et de son article 5, bioMérieux déclare ci-après les transactions réalisées sur ses actions propres pour la période du 15 au 21 novembre 2019. Présentation agrégée par jour et par marché Nom de l'émetteur Code Identifiant de l'émetteur Jour de la transaction Code identifiant de l'instrument financier Volume total journalier (en nombre d'actions) Prix pondéré moyen journalier d'...

December 2, 2019 December 2, 2019 1 FR

Ferragamo Q1 24: operating performance remains underwhelming

Yesterday, Ferragamo published another disappointing quarter with Q1 24 sales down -17% FX-n. Both retail and wholesale channel sales were down and sales declined in every region. As the environment remains complicated for brands in turnaround, we do not expect to see an inflection point in Ferraga

21h / 52m 21h / 52m 1 EN

Paul Charpentier

Paul Charpentier

Nexi - Solid start to the year

Nexi reported solid numbers in Q1 2024 with 6.0% revenue growth that was 70bp above expectations. As the consensus already factors in a deceleration in organic growth and a contained increase in profitability for FY2024e, we see limited downside to current expectations. Given that the valuation mul

May 9, 2024 May 9, 2024 1 EN

Oscar Haffen Lamm

Oscar Haffen Lamm

MedinCell: Continues to deliver! We are confident on the safety readout

Yesterday, Teva and MedinCell announced positive phase 3 efficacy results from its phase 3 trial evaluation mdc-TJK (TEV-'749), a LAI olanzapine, as a once-monthly SC LAI in adults with Schizophrenia. The study met its primary endpoint achieving stat. sig. reductions across all three mdc-TJK doses

May 9, 2024 May 9, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN